Samsung Biologics的动态

Pharmaceutical and health care professionals in Guyana recently benefited from a study tour to Lithuania and Poland to explore cutting edge practices. Learn more: https://lnkd.in/e495Nh_w Lithuania, Poland and Guyana are parties to the CARIFORUM-EU Economic Partnership Agreement which seeks to promote partnership and cooperation between CARIFORUM States such as Guyana and European counterparts such as Lithuania and Poland in areas such as innovation and transfer of technology. The CARIFORUM Directorate at the CARIFORUM Secretariat coordinates implementation of the Agreement by CARIFORUM States?

Attention--Japanese leading clinical #CRO A2 Healthcare has launched its?Boston office?to help accelerate the rapid expansion of its US Pipeline Accelerator Program (#PAP). The company is offering financial #incentives?–?both contract?services and project financing?–?for select US #biotech pipelines to support their clinical-stage development, particularly for entering the Japan and Taiwan markets where 72 percent of drugs approved in Europe and the United States were not approved in 2020. A2 Healthcare's PAP can be a game changer for global biotech companies that are responsible for more than half of the domestically unapproved drugs in #Japan.?

Yesterday, we had an excellent online discussion with Ekonomikos ir inovacij? ministerija vice-minister Neringa Morozaite-Rasmussen, representatives from EuropaBio - the European Association for Bioindustries, and Novartis. The conversation focused on the European Union's competitive advantage in life sciences innovation and addressed critical pharmaceutical legislation challenges. A special thank you to LithuaniaBIO vice-president Agne Vaitkeviciene for initiating this discussion and to Invest Lithuania for organizing the meeting. Wojciech Nowak, MA, IMD EMBA and Claire Skentelbery provided a comprehensive overview of the current situation and valuable insights on what would keep Lithuania competitive and make it more attractive to international pharma and biotech players. We are optimistic that such meetings will contribute to the growth and competitiveness of the Lithuanian and Baltic States life science sector and help establish a robust #regulatory framework. BIOCONNECT

KELIX bio, a Mubadala company, has acquired DiabTec LLC, further strengthening our position in the MENA life sciences sector. This acquisition marks the fifth strategic move for KELIX bio since its acquisition in March 2024, enhancing its biomanufacturing capabilities. ? DiabTec’s state-of-the-art facility, which is built to EU/US FDA standards and is currently the only one in the GCC of this kind, bolsters Mubadala’s efforts to advance local manufacturing and support global insulin supply.

As we continue to strengthen our position in the life sciences sector, today we are proud to announce the acquisition of Diabtec LLC, a subsidiary of Julphar. This strategic acquisition enables us to address critical global challenges including the growing prevalence of diabetes, and demand for microbial based products such as insulin analogues and GLP-1s to treat such conditions locally and abroad.

?? Nordic Biotechs Beyond Borders:?Public-Stage Nordic Biotech’s in Today's Markets Join our panel of #BiotechLeaders as they discuss: ·??The current state of the public markets ·??Effective strategies for Nordic biotechs to enter and establish a foothold in new international markets, including considerations for regulatory compliance and cultural nuances ·??The importance of building robust global networks and partnerships, exploring how collaborations with international stakeholders contribute to market access, distribution, and product adoption. ·??How public stage Nordic biotechs can navigate the complexities of sustaining growth, maintaining innovation momentum, and meeting the expectations of shareholders and the broader market post-IPO ·??How strategic partnerships and collaborations contribute to market presence, product development, and overall competitiveness ?? Hear from: · Don deBethizy, Member Board of Directors, argenx · Renee Aguiar-Lucander, CEO, Calliditas Therapeutics · Jens Lindberg, CEO, Medivir AB · Per Andersson, CEO, XSPRAY PHARMA AB (PUBL) · S?ren Bregenholt, CEO, Alligator Bioscience AB · G?ran Forsberg, CEO, Cantargia AB Find out more: https://lnkd.in/ew-Xj7d8 #LSXNordic #Biotech

Dimerix Limited secures a development and license agreement for Japan, marking a key milestone in its global strategy to deliver innovative therapies. Learn more: https://hubs.li/Q031DH7L0 #Biotech #Innovation #Dimerix

Please find below the new report on Life Sciences Investment in the EU unveiled by FTI Consulting and EUCOPE - European Confederation of Pharmaceutical Entrepreneurs. https://lnkd.in/eVtMxCaC Worth a read. Seroba. with Bruno Montanari was happy to participate in this initiative from the investors perspective, and in this pivotal moment for Europe as recently stressed out by the Mario Draghi report. Some key takeaways: the EU benefits from world-class academic research and innovation, but it also faces challenges such as limited availability and access to EU capital, as well as complex market access procedures. The report also aims to draw up a series of recommendations to enhance the EU's attractiveness for LifeSciences investments and to improve access to innovative medicines in Europe. Thank you to FTI Consulting, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs and Broadreach Global. #FuellingInnovation #Europe #Biotech #Seroba

Spain has climbed the R&D ladder in recent years, and has made it to the top as one of the world leaders in the life science industry. ???? The country is involved in one out of every three tests that are launched in Europe, and comes second in the world in participating in clinical trials. ?? Spain’s leadership in clinical research is rooted in collaborations within the region. ?? Labiotech spoke to Raúl Martín-Ruiz, partner at Ysios Capital Partners, about Spain’s rise as a global leader in clinical studies. ?? Read our latest article to find out more! ?? https://lnkd.in/dPz-HPDe #Biotech #Clinicaltrials #Spain #Research #RD #Collaboration #Partnerships #Researchanddevelopment AseBio - Asociación Espa?ola de Bioempresas | El Pais | FARMAINDUSTRIA | CDTI Innovación - Centro para el Desarrollo Tecnológico y la Innovación | ROVI Pharmaceutical Company | Insud Pharma | Biocat, BioRegion of Catalonia

?? Exciting Updates Ahead! ?? Daniel Chancellor and Isma Hachi, PhD have been working on a series of teasers leading up to their speaking session, “Knowing Me, Knowing You: A Tête-à-Tête on Global Trends and the Next Wave of Biopharma Innovation” on November 4th at 1 PM CET at BIO-Europe. In this first teaser, we dive into key insights on the global biopharma pipeline. Here’s a snapshot of what’s happening in the industry: 1?? Asset growth continues strong, with a 7% increase in 2023, bringing the total to around 23,000 assets. 2?? There are now over 10,000 clinical-stage drugs in the pipeline. 3?? Phase III trials have crossed the 1,000-mark milestone. 4?? China and drug platforms are driving the majority of growth. 5?? Europe’s share of the pipeline has dropped from 45% to 22% over the last 15 years. 6?? Products from China-headquartered companies now account for 29% of the R&D pipeline—up from 16% five years ago, and just 1% in 2008! 7?? The US share has fallen from 42% to 34% in the same period, though the absolute number of trials remains stable (1,707 in 2008 vs. 1,704 in 2023). ?? Have questions you’d like us to cover during the BioEurope session? Drop them in the comments below, and we’ll address them during the event! And this is just the beginning! More insights are coming your way in the weeks ahead. Stay tuned for the next teaser! #BioEurope #Biopharma #Innovation #EBDGroup #Norstella #IQVIA